The project is financed by the Spanish Ministry of Science, innovation and Universities (Ministerio de Ciencia, Innovación y Universidades) and co-financed by the European Regional Development Fund (ERDF; known as FEDER in Spain). It corresponds to the 2019 Challenge-Collaboration (Retos-Colaboración) call of the Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad, aimed at promoting technological development, innovation, and high-quality investigation.
It represents funding of 1.98 M euros over 3 years (2020-2023), distributed between Peptomyc (1.293.695,64 euros loan) and the Vall d’Hebron Institute of Oncology (688.225,48 euros grant), which are joining forces for this project.
The project title is “Identification of clinical biomarkers of response to MYC inhibition in cancer treatment” (“Identificación de Biomarcadores clínicos de respuesta a la inhibición de Myc en el tratamiento del cáncer”), with code RTC2019-007067-1
This is a very significant round of funding and further shows the strong support for this project both within Spain and the European Commission. It will help to advance development of the Omomyc peptide towards its clinical use for cancer treatment.